Related Experiment Video
Updated: Jan 30, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Targeting mTORC1/2 with OSI-027 inhibits proliferation and migration of keloid keratinocytes
1Department of Dermatology and Dermatologic Surgery, Shanghai Ninth People's Hospital, Affiliated to Shanghai Jiaotong University School of Medicine, Center for Specialty Strategy Research of Shanghai, JiaoTong University China Hospital Development Institute, Shanghai, China.
Abstract:
Keloid is a dermal proliferative disorder characterized by the excessive proliferation and migration of keratinocytes and fibroblasts. Over-activation of the serine/threonine protein kinase, mammalian target of rapamycin (mTOR), plays a pivotal role in the process. Here, we show that both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) were hyper-activated in keloid-derived primary keratinocytes. Further, OSI-027, an mTOR kinase inhibitor, potently inhibited proliferation and migration of keloid keratinocytes. At the molecular level, OSI-027 disrupted the assembly of mTORC1 (mTOR-Raptor) and mTORC2 (mTOR-Rictor-mLST8). Further, OSI-027 almost completely blocked the phosphorylation of the mTORC1 substrates, S6K1, S6 and 4EBP1, and the mTORC2 substrate, AKT, at Ser-473. The OSI-027 treatment of keloid keratinocytes showed more effectively inhibited cell proliferation and migration compared to the mTORC1 inhibitor, rapamycin. Moreover, restoring mTORC1 activation by the introduction of the constitutively active S6K1 only partly alleviated OSI-027-induced inhibition of keloid keratinocytes. Notably, mTOR2 inhibition by Rictor siRNAs also inhibited keloid keratinocyte proliferation and migration, but less efficiently than OSI-027. Together, our results imply that concurrent targeting of mTORC1/2 by OSI-027 potently inhibits the proliferation and the migration of keloid keratinocytes. Thus, OSI-027 may have translational value for the treatment of keloid.
Insights
The study found that OSI-027, an inhibitor of mammalian target of rapamycin (mTOR) kinase, effectively reduced keloid keratinocyte proliferation and migration by inhibiting both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). This suggests OSI-027
Area of Science:
- Dermatology
- Molecular Biology
- Cell Biology
Background:
- Keloids are characterized by excessive keratinocyte and fibroblast proliferation and migration.
- Hyper-activation of the mammalian target of rapamycin (mTOR) pathway is implicated in keloid pathogenesis.
Purpose of the Study:
- To investigate the role of mTOR complexes 1 and 2 (mTORC1/2) in keloid keratinocytes.
- To evaluate the efficacy of the mTOR kinase inhibitor OSI-027 in targeting keloid cell proliferation and migration.
Main Methods:
- Primary keloid keratinocytes were treated with OSI-027.
- mTORC1 and mTORC2 complex assembly and substrate phosphorylation were assessed.
- Cell proliferation and migration assays were performed.
- Comparisons were made with rapamycin (mTORC1 inhibitor) and Rictor siRNA (mTORC2 inhibition).
Main Results:
- Both mTORC1 and mTORC2 were hyper-activated in keloid keratinocytes.
- OSI-027 potently inhibited keloid keratinocyte proliferation and migration.
- OSI-027 disrupted mTORC1 and mTORC2 complex assembly and blocked key substrate phosphorylation.
- OSI-027 demonstrated superior efficacy compared to rapamycin and Rictor siRNA.
Conclusions:
- Concurrent targeting of mTORC1/2 by OSI-027 effectively inhibits keloid keratinocyte proliferation and migration.
- OSI-027 shows potential as a therapeutic agent for keloid treatment.
Related Concept Videos
Feedback Inhibition
Abnormal Proliferation
Migration
Enzyme Inhibition
Cell Migration
Cell Migration

